

Bixby, D., & Talpaz, M. (2010). Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. *Leukemia*, 25(1), 7-22.

Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., ... & Fielding, J. W. L. (2002). Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. *British journal of cancer*, 86(12), 1864-1870.

Brekken, R. A., Huang, X., King, S. W., & Thorpe, P. E. (1998). Vascular endothelial growth factor as a marker of tumor endothelium. *Cancer research*, 58(9), 1952-1959.

Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., & Cheresch, D. A. (1998). Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. *Cell*, 92(3), 391-400.

Brown, P. D., & Giavazzi, R. (1995). Matrix metalloproteinase inhibition: A review of anti-tumour activity Matrix metalloproteinase inhibition: A review of anti-tumour activity. *Annals of Oncology*, 6(10), 967-974.

Burger, R. A. (2011). Overview of anti-angiogenic agents in development for ovarian cancer. *Gynecologic oncology*, 121(1), 230-238.

Campbell, S. C., Volpert, O. V., Ivanovich, M., & Bouck, N. P. (1998). Molecular mediators of angiogenesis in bladder cancer. *Cancer research*, 58(6), 1298-1304.

Cao, R., Farnebo, J., Kurimoto, M., & Cao, Y. (1999). Interleukin-18 acts as an angiogenesis and tumor suppressor. *The FASEB Journal*, 13(15), 2195-2202.

Carmeliet, P. (2003). Angiogenesis in health and disease. *Nature medicine*, 9(6), 653-660.